Attorney Michael Brady Lynch Will Lecture on Blood Thinner Litigation for Mass Tort Nexus
Attorney Michel Brady Lynch, Esq. of The Michael Brady Lynch Firm in Winter Park will speak on September 16 in Ft. Lauderdale at Mass Tort Nexus’ highly regarded Four Day Immersion Course. Attorney Lynch has prepared a deep-dive into Pradaxa and Xarelto litigations. This course unites attorneys from all over the United States to hear leaders
Read More
Xarelto Litigation Heads to Trial
The U.S. District Judge Eldon E. Fallon overseeing more than 18,000 Xarelto lawsuits ordered that hundreds of those cases be prepared for two waves as the blood thinner litigation heads to trial. Each wave will have 600 lawsuits. The Plaintiffs Steering Committee, Defendants Counsel and the Court will each select 200 cases for each wave. The
Read More
Aspirin As Effective As Xarelto For Post-Surgical Bleeds
Researchers studying the effects of Xarelto and aspirin use post surgery found no notable difference in post-surgical bleeds between the two. In fact, the only difference between Xarelto and aspirin is cost. Consumers pay around $425 a month for Xarelto compared to a dollar for aspirin. About Xarelto Anticoagulants, commonly known as blood-thinners, work by
Read More
Xarelto Still Without an Antidote
FDA announced that Bayer’s popular blood thinner, Xarelto, will still not have an approved antidote. The government agency will not approve the antidote, AndexXa, without additional information from the manufacturer, Portola. This pushes back the possible approval date to May 2018. About Xarelto Approved by the FDA in 2011, Xarelto is used to reduce
Read MoreNew Nurse Training Could Force Patients on Certain Blood Thinners
More people are refusing to take the dangerous blood thinners Xarelto and Pradaxa. Therefore, pharmaceutical companies are finding creative workarounds. They are funding studies and online training programs centered on teaching nurses to convince patients to use these dangerous medications. Plus, informing nurses on what to say when a patient refuses to take these blood thinners.
Read More
Jury Orders $27.8M in Damages in Xarelto Trial
In the first plaintiff win, a jury orders Xarelto manufacturers Johnson & Johnson and Bayer to pay $27.8 million in damages. The manufacturers won the first three cases in Louisiana and Mississippi, however, this shows that justice does eventually prevail. About Xarelto Approved by the FDA in 2011, Xarelto is used to reduce the
Read More
First Philadelphia Xarelto Trial Underway
The first Philadephia Xarelto trial started this month. Even though three bellwether trials have already occurred in Louisiana, this will be the first case that went to trial out of the 1,500 Xarelto cases filed there. There are five additional cases scheduled for trial in Philadelphia but those trials will not begin until January 16,
Read More
New Xarelto Study Says The Drug Is Even More Dangerous When Combined with Other Medications
A new study suggests that bleeding events while using Xarelto may increase if other medications are also being used. The study found those containing amiodarone (Rifadin, Diflucan, and Dilantin) to be the most severe. How many more drug combinations are there that have not been discovered yet? When will the FDA take a stand and
Read MoreNAVIGATE ESUS Study Says Xarelto No More Effective Than Aspirin
The manufacturers of Xarelto (rivaroxaban), Bayer and Janssen stopped phase III of the NAVIGATE ESUS study early, when researchers showed the drug did not prevent stroke or increased bleeding better than over the counter aspirin. This screams an attempt by the manufacturers trying to get FDA approval for another use of the medication. Bayer and
Read More
Xarelto vs Pradaxa
Warfarin was a doctor’s prescription choice of blood thinner for 60 years. Then, came Xarelto and Pradaxa. Both are part of a new wave of blood thinners. Manufacturers designed these drugs to prevent the risks of warfarin such as brain hemorrhages and other bleeding events. Plus, these blood thinners don’t require as frequent monitoring and
Read More